INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLINDED, PHASE 3 STUDY OF VORASIDENIB VERSUS PLACEBO IN PATIENTS WITH RESIDUAL OR RECURRENT GRADE 2 GLIOMA WITH AN IDH1/2 MUTATION
Catherine McBain, Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal et autres
Abstract AIMS Current treatments grade 2 gliomas are not curative and can be associated with short- and long-term toxicities. Vorasidenib (VOR), an oral, brain-penetrant, dual inhibitor of mutant (m)IDH1/2 enzymes, has shown a tolerable safety profile and preliminary clinical activity in phase …
gb, us, nl, il, fr, ca, ch, es, de, it (code pays fourni par la source)
3 citations
Neuro-Oncology